



Attorney's Docket No. 5405-252

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Rizzieri et al.

Confirmation No.: 5735

Serial No.: 10/008,062

Group Art Unit: 1642

Filed: October 19, 2001

Examiner: Alana M. Harris

For: ANTI-TENASCIN MONOCLONAL ANTIBODY THERAPY FOR LYMPHOMA

September 22, 2005

Mail Stop RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)**

Sir:

Attached is a list of documents on form PTO-1449 together with a copy of each document. It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP.

This Information Disclosure is submitted in accordance with 37 C.F.R. § 1.97(b)(4), before the mailing of a first action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,

Shawna Cannon Lemon

Registration No. 53,888

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428, Raleigh, NC 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792

CERTIFICATE OF EXPRESS MAILING

Express Mail Label No. EV 674756836 US

Date of Deposit: September 22, 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan E. Freedman

Date of Signature: September 22, 2005

Sheet	1	of	1
-------	---	----	---

Sheet	1	of	1
-------	---	----	---

1 OIPE IAP63
SEP 22 2005
PATENT & TRADEMARK

Attorney Docket Number	5405-252
------------------------	----------

[illegible][illegible]

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	2	Supplementary Partial European Search Report, EP 01 99 6085, 07/06/2005	
	3	Kaminski et al., "Radioimmunotherapy with iodine ¹³¹ I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience", <u>Blood</u> , 96(4):1259-1266 (2000)	

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.